Page 6,578«..1020..6,5776,5786,5796,580..6,5906,600..»

SmallCapVoice Announces a New Audio Interview With Dr. Simon Craw, Executive Vice President of International Stem Cell …

Posted: Published on August 23rd, 2012

AUSTIN, Texas, Aug. 23, 2012 (GLOBE NEWSWIRE) -- SmallCapVoice announced today that a new audio interview with International Stem Cell Corporation (ISCO) (www.internationalstemcell.com), a California-based biotechnology company focused on therapeutic and research products, is now available. The interview can be heard at http://smallcapvoice.com/blog/8-16-12-smallcapvoice-interview-with-international-stem-cell-corporation-otcbb-isco The interview includes an overview of the markets being targeted by ISCO and its subsidiary companies, the goals for the companies in 2012, and the major achievements of the companies to date. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell(TM). ISCO also produces and markets specialized cells and growth media for … Continue reading →

Posted in Stem Cell Research | Comments Off on SmallCapVoice Announces a New Audio Interview With Dr. Simon Craw, Executive Vice President of International Stem Cell …

Stem cells: A culture war gone quiet

Posted: Published on August 23rd, 2012

While a draft plank in the Republican Partys platform supporting a constitutional amendment banning abortion has gotten plenty of attention, so far unnoticed is another culture war provision tucked right alongside it an opposition to federal funding for embryonic stem cell research. We oppose the killing of embryos for their stem cells. We oppose Federal funding of embryonic stem cell research, the draft language reads, mirroring previous years platforms. Youd be forgiven for having dj vu from 2004, when stem cell research was at the top of the agenda of both parties and sparked fierce and emotional debate. Its completely vanished from the political scene since what happened? Stem cells used to be one of the big three social issues dividing Americans, along with abortion and gay rights. It was a cultural debate engulfing our country today, as then-Kansas Sen. and now Gov. Sam Brownback, a staunch social conservative, saidin 2004. The issue played a major role in that years presidential race, with Democrat John Kerry suggesting that millions of lives were at stake by President Bush preventing federal funds from going to the medical research. Bush, buoyed into office by the Christian right, opposed the taxpayer dollars going to … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cells: A culture war gone quiet

International Stem Cell Corp to Present at the Southern California Investor Conference on August 30, 2012

Posted: Published on August 23rd, 2012

CARLSBAD, CA--(Marketwire -08/23/12)- International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, announced today that Dr. Simon Craw, Executive Vice President of Business Development and Investor Relations, will present at the 2012 Southern California Investor Conference on Thursday, August 30, 2012, at 2:30 pm PT / 5:30 pm ET. The conference will be held at the Marriott Hotel in Newport Beach, California. Southern California Investor ConferenceDate: Thursday, August 30, 2012 Time: 2:30 pm PT / 5:30 pm ET Location: Marriott Hotel, Newport Beach, CA Please contact the conference organizers if you have an interest in attending these conferences or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting with management. Conference participation is limited by capacity and registration is required. For more information on the conference, please visit the conference website at http://www.californiastocks.com. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. … Continue reading →

Posted in Stem Cell Research | Comments Off on International Stem Cell Corp to Present at the Southern California Investor Conference on August 30, 2012

Gene Detectives Find New Tool to Contain Deadly Bacteria

Posted: Published on August 23rd, 2012

By Michelle Fay Cortez - 2012-08-23T04:01:00Z Scientists using rapid genetic testing to track the path of a deadly bacterium in a Maryland medical center discovered unsuspected ways pathogens can spread and learned a new tool to combat hospital-acquired infections. The DNA screening allowed staff at the National Institutes of Healths research hospital in Bethesda, Maryland, to link infections with a multidrug resistant strain of Klebsiella pneumoniae weeks after the first case was found, even though there were no obvious ties among the patients. Uncovering the way the bacteria moved silently though the hospital for weeks confirmed an outbreak was under way and prompted aggressive measures to control the pathogen that infected 18 people. This has changed the practice of medicine in our hospital and we hope it will change the way other hospitals would control a similar outbreak, said Julie Segre, a senior investigator at the National Human Genome Research Institute. Advances in genetic sequencing allowed researchers to map minute differences in the DNA of the bacterium in less than a week, proving all 18 cases began with a single patient in June 2011. The first patient, a 43-year-old New York woman, was isolated as soon as she arrived at … Continue reading →

Comments Off on Gene Detectives Find New Tool to Contain Deadly Bacteria

Genetic sleuths track down deadly superbug

Posted: Published on August 23rd, 2012

WASHINGTON Over six frightening months, a deadly germ untreatable by most antibiotics spread in the nations leading research hospital. Pretty soon, a patient a week was catching the bug. Scientists at the National Institutes of Health locked down patients, cleaned with bleach, even ripped out plumbing and still the germ persisted. By the end, 18 people harbored the dangerous germ, and six died of bloodstream infections from it. Another five made it through the outbreak only to die from the diseases that brought them to NIHs world-famous campus in the first place. It took gene detectives teasing apart the bacterias DNA to solve the germs wily spread, a CSI-like saga with lessons for hospitals everywhere as they struggle to contain the growing threat of superbugs. It all stemmed from a single patient carrying a fairly new superbug known as KPC Klebsiella pneumoniae that resists treatment by one of the last lines of defense, antibiotics called carbapenems. We never want this to happen again, said Dr. Tara Palmore, deputy hospital epidemiologist at the NIH Clinical Center. Infections at health care facilities are one of the nations leading causes of preventable death, claiming an estimated 99,000 lives a year. Theyre something of … Continue reading →

Comments Off on Genetic sleuths track down deadly superbug

Stem cell research may have application to treat autism

Posted: Published on August 23rd, 2012

SACRAMENTO, Calif. Rydr Rudgers suffers from cerebral palsy. He couldnt move or talk before a cord blood stem cell treatment undertaken during a Duke University study. His doctor, Michael Chez, M.D. is medical director of Pediatric Neurology at Sutter Neuroscience Institute. He is now heading up the first stem cell clinical trial on autism and hopes for similar results. Dr. Chez says autism shares some of the same symptoms as cerebral palsy and that there is plenty of anecdotal evidence that using cord blood stem cells from the patients own umbilical cord can regenerate brain cells. The study which will employ placebos will determine scientifically whether such treatments make improvements in young autism patients. Sutter Neuroscience Institute got FDA approval for the landmark study and will enroll 30 kids with autism age 2 to 7 to receive injections of their own stem cells. Most parents are given the option of saving their childrens ubilical cords after birth. Elisa Rudgers is glas she did. Now four years old, Rydr is walking, talking and eating on his own. That wasnt possible without three stem cell therapy injections over several years. After each injection he made a marked improvement in motor skills. Its … Continue reading →

Comments Off on Stem cell research may have application to treat autism

TiGenix Business Update & Financial Highlights for the First Half of 2012

Posted: Published on August 23rd, 2012

LEUVEN, BELGIUM--(Marketwire -08/23/12)- TiGenix NV (EURONEXT:TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. Business highlights Financial highlights "The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601." Business update Commercial roll-out of ChondroCelect continues to gain momentum ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011. Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In … Continue reading →

Posted in Cell Therapy | Comments Off on TiGenix Business Update & Financial Highlights for the First Half of 2012

TiGenix Business Update & Financial Highlights for the First Half of 2012

Posted: Published on August 23rd, 2012

LEUVEN, BELGIUM--(Marketwire -08/23/12)- TiGenix NV (EURONEXT:TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. Business highlights Financial highlights "The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601." Business update Commercial roll-out of ChondroCelect continues to gain momentum ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011. Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In … Continue reading →

Posted in Cell Therapy | Comments Off on TiGenix Business Update & Financial Highlights for the First Half of 2012

Many Teens Drinking, Taking Drugs During School: Survey

Posted: Published on August 23rd, 2012

By Amanda Gardner HealthDay Reporter WEDNESDAY, Aug. 22 (HealthDay News) -- Ninety percent of American high school students report that some of their classmates are using illicit drugs, including alcohol and tobacco, during the school day, a new survey found. When asked to estimate how many were involved, these teens reported that about 17 percent of students -- roughly 2.8 million -- are abusing drugs during the school day, according to the survey. "The findings are alarming but not surprising," said Bruce Goldman, director of substance abuse services at Zucker Hillside Hospital, in Glen Oaks, N.Y. "We know that teens abuse alcohol, cannabis, prescription medications. It makes sense that they do it at school where they congregate with their peers. Goldman was not involved with the survey, which was released Wednesday by the National Center on Addiction and Substance Abuse at Columbia University (CASAColumbia), in New York City. The survey is a timely one, coming out soon after a U.S. government study found that more teenagers start drinking and smoking cigarettes and marijuana in June and July than in any other month. The new survey also found that schools can be a hub of drug-dealing activity, with 44 percent of … Continue reading →

Posted in Drugs | Comments Off on Many Teens Drinking, Taking Drugs During School: Survey

Successful Growth of BioDiem's Virus in VIVALIS EB66(R) Cell Line

Posted: Published on August 23rd, 2012

ROUSSAY, FRANCE--(Marketwire -08/21/12)- Successful growth of BioDiem's Virus in VIVALIS EB66() Cell Line Highlights: * BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66() cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known techniques to demonstrate the creation of new, 'disarmed' viruses (vectors) carrying foreign antigens that can be customized to fight specific diseases. * Both BioDiem's LAIV virus and VIVALIS' EB66 have produced vaccines which have been through Phase II clinical trials, facilitating commercialisation. Melbourne (Australia), Nantes (France), 21 August 2012: Australian infectious disease therapy and vaccine development company BioDiem Ltd (BDM.AX) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66( )cell line. The next stage of the collaboration between BioDiem and VIVALIS will use known techniques to modify the LAIV virus to demonstrate and optimize the methodology for making a customizable "vector" which could be used by vaccine developers for the development of new vaccines targeting other specific diseases. Priority disease targets include nasopharyngeal carcinoma and respiratory syncytial … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Successful Growth of BioDiem's Virus in VIVALIS EB66(R) Cell Line

Page 6,578«..1020..6,5776,5786,5796,580..6,5906,600..»